ArticleCellular and molecular life sciences : CMLS2022

A novel combination treatment of antiADAM17 antibody and erlotinib to overcome acquired drug resistance in non-small cell lung cancer through the FOXO3a/FOXM1 axis.

Junnan Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.